Meeting
2016 ASCO Annual Meeting
Health care resource utilization (HCRU) in relapsed/refractory multiple myeloma (RRMM): Results from PREAMBLE.
Authors
Hartmut Goldschmidt
Heidelberg University Hospital, Heidelberg, Germany
Hartmut Goldschmidt , Ravi Vij , David Kuter , David Cella , Teresa Maria Zyczynski , Catherine C. Davis , Sergey Popov , Gordon Cook
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research and Quality of Care
Track
Health Services Research and Quality of Care
Sub Track
Value/Cost of Care
Clinical Trial Registration Number
NCT01838512
Citation
J Clin Oncol 34, 2016 (suppl; abstr 6621)
DOI
10.1200/JCO.2016.34.15_suppl.6621
Abstract #
6621
Poster Bd #
104
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 1 study of tasquinimod, an S100A9 inhibitor, alone and in combination with IRd for relapsed and refractory multiple myeloma (RRMM).
First Author: Dan T. Vogl
Poster
2023 ASCO Annual Meeting
Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail patients with RRMM: Results of the multicenter phase 2 study (IFM 2018-02) of the Intergroupe Francophone du Myélome (IFM).
First Author: Cyrille Touzeau
Poster
2017 ASCO Annual Meeting
Daratumumab-based combination therapies (DCT) in heavily-pretreated patients (pts) with relapsed and/or refractory multiple myeloma (RRMM).
First Author: Arjun Lakshman
Poster
2016 ASCO Annual Meeting
Adverse event (AE) management in patients (pts) with relapsed and refractory multiple myeloma (RRMM) taking pomalidomide (POM) plus low dose-dexamethasone (LoDEX): A pooled analysis from 3 clinical trials.
First Author: Philippe Moreau